Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. IBM
6. PRIM
7. SPY
8. ACN
9. NVDA
10. BLZE

Go back to Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
Grifols Sa Barcelona Sponsored ADR (AMEX: GIKLY) Delayed: 5.06 -0.63 (11.07%)
Previous Close $5.69    52 Week High $24.05 
Open $5.06    52 Week Low $9.74 
Day High $5.06    P/E N/A 
Day Low $5.06    EPS $0.00 
Volume 192       

EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) Delayed: 10.06 +0.09 (0.90%)
Previous Close $9.97    52 Week High $21.75 
Open $10.00    52 Week Low $6.41 
Day High $10.06    P/E N/A 
Day Low $10.00    EPS $0.00 
Volume 846       

GRIFOLS SP ADR-B (NASDAQ: GRFS) Delayed: 7.19 -0.09 (1.24%)
Previous Close $7.28    52 Week High $35.35 
Open $7.38    52 Week Low $14.07 
Day High $7.40    P/E N/A 
Day Low $7.16    EPS $0.00 
Volume 459,093       

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Delayed: 35.74 +0.01 (0.03%)
Previous Close $35.73    52 Week High $4.38 
Open $35.85    52 Week Low $1.88 
Day High $36.50    P/E N/A 
Day Low $35.70    EPS $-1.12 
Volume 141,015